Abstract

Introduction: The latest paradigm proposes that imbalance of Treg and Th17 cells play a significant role in Systemic Lupus Erythematosus (SLE) pathogenesis. The influence of IL-23 and IL-17 on the pathogenesis of SLE remains controversial. This study aimed to observe the role of IL-23/IL17 axis in the pathogenesis of SLE as disease activity using Systemic Lupus Activity Measure (SLAM) index.
Methods: This cross-sectional study analyzed thirty blood serum specimens taken from female patients with SLE diagnosed by the 1997 ACR criteria. All samples were analyzed for IL-23 and IL-17 serum level using ELISA method. Pearson’s/Spearman’s correlation test and Path analysis were used for statistical analysis.
Results: Thirty female subjects aged 31.3±10.46 years all manifested with hematology abnormalities and arthritis posed as the most common clinical manifestation. Both IL-23 and IL-17 levels increased at 625.33 pg/mL and 34.53 pg/mL, respectively. Disease activity resulted in a high mean SLAM score of 29.3±3.9. No correlation was found between serum IL-23 and serum IL-17 (r=0.089; p>0.05). Furthermore, IL-17 and IL-23 did not significantly correlate to disease activity (r=0.026; p>0.05); (r=0.116; p>0.05).
Conclusion: There was no significant correlation between IL-23 and IL-17 with SLE disease activity.

References

  • Adam FM, Nara MG, & Adam JM, (2006) Fasting insulin, adiponectin, hs-CRP levels, and the components of metabolic syndrome. Acta medica Indonesiana 38(4): 179–184.
  • Bertsias G, Cervera T, & Boumpas D, (2017) Systemic lupus erythematosus: pathogenesis and clinical features. 2012. URL: http://www. eular. org/myuploaddata/files/sample% 20chapter20_mod
  • Birmingham DJ, Irshaid F, Nagaraja HN, Zou X, Tsao BP, Wu H, Yu CY, Hebert LA, & Rovin BH, (2010) The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus 19(11): 1272–1280.
  • Chaichian Y, & Utset TO, (2013) Targeted therapies in systemic lupus erythematosus: a state-of-the-art review. J Clin Cell Immunol S 6: 2.
  • Cheng F, Guo Z, Xu H, Yan D, & Li Q, (2009) Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythematosus. Annals of the rheumatic diseases 68(4): 604–606.
  • Crispín JC, Kyttaris VC, Terhorst C, & Tsokos GC, (2010) T cells as therapeutic targets in SLE. Nature Reviews Rheumatology 6(6): 317.
  • Du J, Li Z, Shi J, & Bi L, (2014) Associations between serum interleukin-23 levels and clinical characteristics in patients with systemic lupus erythematosus. Journal of international medical research 42(5): 1123–1130.
  • Galil SMA, Ezzeldin N, & El-Boshy ME, (2015) The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis. Cytokine 76(2): 280–287.
  • Ghanima ATA, Elolemy GG, Ganeb SS, Elazem AAA, & Abdelgawad ER, (2012) Role of T helper 17 cells in the pathogenesis of systemic lupus erythematosus. Egypt J Immunol 19: 25–33.
  • Handono K, Hasanah D, Kalim H, & Mawarti H, (2013) The association among serum levels of vitamin D, TGF-β/IL-6 balance and Treg/Th17 balance in systemic lupus erythematosus patients in Indonesia. International Journal of Biochemistry and Biotechnology 2(9): 490–496.
  • Jakes RW, Bae S, Louthrenoo W, Mok C, Navarra S V, & Kwon N, (2012) Systematic review of the epidemiology of systemic lupus erythematosus in the Asia‐Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis care & research 64(2): 159–168.
  • Leng R-X, Pan H-F, Chen G-M, Wang C, Qin W-Z, Chen L-L, Tao J-H, & Ye D-Q, (2010) IL-23: a promising therapeutic target for systemic lupus erythematosus. Archives of medical research 41(3): 221–225.
  • Mak TW, Saunders ME, and Je BD, (2014) Primer to the Immune Response. Second Edi $ on. AP Cell. Elsevier) London, UK
  • Marpaung B, Ginting AR, & Sjah OKM, (2018) Serum midkine levels in systemic lupus erythematosus. Open Access Macedonian Journal of Medical Sciences 6(8): 1323–1327. https://doi.org/10.3889/oamjms.2018.315
  • Martin JC, Baeten DL, & Josien R, (2014) Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus. Clinical immunology 154(1): 1–12.
  • Maule WJ, (2011) Pathogenesis & future treatments of systemic lupus erythematosus: the role of cytokines and anti-cytokines?: peer reviewed review. Medical Technology SA 25(1): 5–17.
  • McCarthy EM, Smith S, Lee RZ, Cunnane G, Doran MF, Donnelly S, Howard D, O’Connell P, Kearns G, & Ní Gabhann J, (2014) The association of cytokines with disease activity and damage scores in systemic lupus erythematosus patients. Rheumatology 53(9): 1586–1594.
  • Moftah RF, & Hassan E-S, (2016) AB0039 Interleukin-17 in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients: Correlation with Clinical Presentation, Laboratory Parameters and Activity Indices. BMJ Publishing Group Ltd
  • Mok MY, Wu HJ, Lo Y, & Lau CS, (2010) The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus. The Journal of Rheumatology 37(10): 2046–2052.
  • Oke V, Brauner S, Larsson A, Gustafsson J, Zickert A, Gunnarsson I, & Svenungsson E, (2017) IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE). Arthritis research & therapy 19(1): 139.
  • Patrick J, Marpaung B, & Ginting Y, (2018) Differences of serum procalcitonin levels between bacterial infection and flare in systemic lupus erythematosus patients. In: L., W., D., W., W., M., J.K., B., P.C., E., M., de J., and U., Z. (eds.) Vol. 125. Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia: Institute of Physics Publishing https://doi.org/10.1088/1755-1315/125/1/012157
  • Puwipirom H, Hirankarn N, Sodsai P, Avihingsanon Y, Wongpiyabovorn J, & Palaga T, (2010) Increased interleukin-23 receptor+ T cells in peripheral blood mononuclear cells of patients with systemic lupus erythematosus. Arthritis research & therapy 12(6): R215.
  • Sabry A, El-husseini A, Mahmoud K, Eldahshan KF, George SK, Abdel-Khalek E, El-Shafey EM, & Abo-Zenah H, (2006) Proinflammatory cytokines (TNF-α and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine 35(3–4): 148–153.
  • Samad R, Akbar FH, Willianto OA, Malinta QU, & Namirah HA, (2019) Effect of scaling and root planing treatment on levels Hs-CRP in Indonesian patients with risk of cardiovascular disease. Pesquisa Brasileira em Odontopediatria e Clinica Integrada 19(1):. https://doi.org/10.4034/PBOCI.2019.191.02
  • Shankar S, & Behera V, (2014) Advances in management of systemic lupus erythematosus. Journal of Mahatma Gandhi Institute of Medical Sciences 19(1): 28.
  • Sibarani H, & Zubir Z, (2018) Systemic lupus erythematosus in a male patient. In: L., W., D., W., W., M., J.K., B., P.C., E., M., de J., and U., Z. (eds.) Vol. 125. Division of Allergy and Immunology, Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia: Institute of Physics Publishing https://doi.org/10.1088/1755-1315/125/1/012158
  • Stritesky GL, Yeh N, & Kaplan MH, (2008) IL-23 promotes maintenance but not commitment to the Th17 lineage. The Journal of Immunology 181(9): 5948–5955.
  • Tanasescu C, Balanescu E, Balanescu P, Olteanu R, Badea C, Grancea C, Vagu C, Bleotu C, Ardeleanu C, & Georgescu A, (2010) IL-17 in cutaneous lupus erythematosus. European journal of internal medicine 21(3): 202–207.
  • Vincent FB, Northcott M, Hoi A, Mackay F, & Morand EF, (2013) Clinical associations of serum interleukin-17 in systemic lupus erythematosus. Arthritis research & therapy 15(4): R97.
  • Wang A, Guilpain P, Chong BF, Chouzenoux S, Guillevin L, Du Y, Zhou XJ, Lin F, Fairhurst A, & Boudreaux C, (2010) Dysregulated expression of CXCR4/CXCL12 in subsets of patients with systemic lupus erythematosus. Arthritis & Rheumatism 62(11): 3436–3446.
  • Wong CK, Lit LCW, Tam LS, Li EKM, Wong PTY, & Lam CWK, (2008) Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clinical immunology 127(3): 385–393.
  • Wuryana D, Suryana BPP, & Yulistiani Y, (2016) Effectivity and renal safety of cyclosporine and methylprednisolone combination therapy in patients with systemic lupus erythematosus (SLE). Folia Medica Indonesiana 51(3): 156–161.
  • Xia LP, Li BF, Shen H, & Lu J, (2015) Interleukin-27 and interleukin-23 in patients with systemic lupus erythematosus: possible role in lupus nephritis. Scandinavian journal of rheumatology 44(3): 200–205.
  • Yanih I, (2016) Quality of Life in Patient with Systemic Lupus Erythematosus (SLE). Jurnal Berkala Epidemiologi 4(1): 1–12.
  • Yao Y, Wang JB, Xin MM, Li H, Liu B, Wang LL, Wang LQ, & Zhao L, (2016) Balance between inflammatory and regulatory cytokines in systemic lupus erythematosus. Genet Mol Res 15(2): 1–8.
  • Zhang Z, Kyttaris VC, & Tsokos GC, (2009) The role of IL-23/IL-17 axis in lupus nephritis. The Journal of Immunology 183(5): 3160–3169.
  • Zhao X-F, Pan H-F, Yuan H, Zhang W-H, Li X-P, Wang G-H, Wu G-C, Su H, Pan F-M, & Li W-X, (2010) Increased serum interleukin 17 in patients with systemic lupus erythematosus. Molecular biology reports 37(1): 81–85.
  • Zickert A, Amoudruz P, Sundström Y, Rönnelid J, Malmström V, & Gunnarsson I, (2015) IL-17 and IL-23 in lupus nephritis-association to histopathology and response to treatment. BMC immunology 16(1): 7.

License

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.